Gastric Ulcer: A Double-Blind Comparison of 100 Mg Pirenzepine plus Antacid Versus 800 Mg Cimetidine plus Antacid

Gonvers, J.-J.; Réalini, S; Bretholz, Adam; Voirol, M; Arnold, J; Birchler, R; Ollyo, J. B.; Guyot, J.; Capitaine, Y

doi:10.3109/00365528609011121

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to the ulcer-healing rate, there were no significant differences between H 2 RAs [52][53][54][55][56][57][58][59]. Moreover, pirenzepine [60], sucralfate [61][62][63][64][65][66][67][68], and misoprostol [69,70] are recommended because each of their ulcer-healing rates was equivalent to those of H 2 RAs. Although vonoprazan could not be cited because the literature was searched from 1983 to 2012, vonoprazan has been receiving much attention in recent years because of its high ulcer-healing rate for gastric ulcers compared with lansoprazole [71].…”

Section: Non-eradication Therapymentioning

confidence: 99%

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology (JSGE) revised the evidence-based clinical practice guidelines for peptic ulcer disease in 2014 and has created an English version. The revised guidelines consist of seven items: bleeding gastric and duodenal ulcers, Helicobacter pylori (H. pylori) eradication therapy, non-eradication therapy, drug-induced ulcer, non-H. pylori, non-nonsteroidal anti-inflammatory drug (NSAID) ulcer, surgical treatment, and conservative therapy for perforation and stenosis. Ninety clinical questions (CQs) were developed, and a literature search was performed for the CQs using the Medline, Cochrane, and Igaku Chuo Zasshi databases between 1983 and June 2012. The guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Therapy is initially provided for ulcer complications. Perforation or stenosis is treated with surgery or conservatively. Ulcer bleeding is first treated by endoscopic hemostasis. If it fails, surgery or interventional radiology is chosen. Second, medical therapy is provided. In cases of NSAID-related ulcers, use of NSAIDs is stopped, and anti-ulcer therapy is provided. If NSAID use must continue, the ulcer is treated with a proton pump inhibitor (PPI) or prostaglandin analog. In cases with no NSAID use, H. pylori-positive patients receive eradication and anti-ulcer therapy. If first-line eradication therapy fails, second-line therapy is given. In cases of non-H. pylori, non-NSAID ulcers or H. pyloripositive patients with no indication for eradication therapy, non-eradication therapy is provided. The first choice is PPI therapy, and the second choice is histamine 2-receptor antagonist therapy. After initial therapy, maintenance therapy is provided to prevent ulcer relapse.

show abstract

Section: Non-eradication Therapymentioning

confidence: 99%

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In a small study on 57 patients with gastric ulcers, cimetidine and pirenzepine lead to similar healing rates after 8 weeks, 83% and 76%, respectively [16].…”

Section: Preventing Stimulation Of the Parietal Cellmentioning

confidence: 99%

Developments in the inhibition of gastric acid secretion

Mössner

Caca

2005

Eur J Clin Investigation

View full text Add to dashboard Cite

Understanding the physiology of gastric acid secretion and the pathophysiology of acidrelated diseases (e.g. gastrooesophageal reflux and peptic ulcer) has led to the development of numerous ways to decrease acid exposure. Pharmacologically one can try to neutralize secreted acid by antacids, prevent stimulation of the parietal cell, improve mucosal defences and block the functioning of the proton pump. Proton pump inhibitors (PPIs) inhibit the final step of acid secretion, and are currently the most potent acid inhibitors. Major therapeutic improvement within the PPI class appears unlikely, as agents in this class share similar chemistry, mode of action, and pharmacokinetic profiles. New approaches that block acid secretion are now being developed. Gastrin (CCK 2 ) receptor antagonists and potassium-competitive acid blockers (P-CABs) are in clinical development.Keywords Gastrin (CCK 2 ) receptor antagonist, gastrooesophageal reflux disease, H + ,K + -ATPase, H 2 -blocker, histamine (H 2 ) receptor antagonist, peptic ulcer, potassium-competitive acid blocker (P-CAB), proton pump inhibitor. Eur J Clin Invest 2005; 35 (8): 469-475

show abstract

Ulcer Treatment–Regimens and Duration of Inhibition of Acid Secretion: How Long to Dose

Bauerfeind

Koelz

1988

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Gastric Ulcer: A Double-Blind Comparison of 100 Mg Pirenzepine plus Antacid Versus 800 Mg Cimetidine plus Antacid

Cited by 3 publications

References 6 publications

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

Developments in the inhibition of gastric acid secretion

Ulcer Treatment–Regimens and Duration of Inhibition of Acid Secretion: How Long to Dose

Contact Info

Product

Resources

About